Maze Therapeutics (MAZE) Assets Average (2025 - 2026)
Maze Therapeutics (MAZE) posted Assets Average of $408.4 million for Q1 2026, little changed sequentially from $409.6 million in Q4 2025, and up 42.46% YoY from $286.7 million in Q1 2025.
Maze Therapeutics (MAZE) Assets Average (2025 - 2026) Analysis & Trends
Maze Therapeutics has reported Assets Average for 2 years, with the latest figure at $408.4 million in Q1 2026.
- Quarterly Assets Average rose 42.46% year-over-year to $408.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.4 million (up 42.46% YoY) and the FY2025 annual result came in at $318.8 million, changed N/A from the prior year.
- Assets Average was little changed at $408.4 million in Q1 2026 per MAZE's latest filing, from $409.6 million in the prior quarter.
- Over five years, Assets Average peaked at $409.6 million in Q4 2025 and troughed at $286.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 475.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 475.67 Mn |
| Mar 31, 2026 | 408.42 Mn |
| Dec 31, 2025 | 409.59 Mn |
| Sep 30, 2025 | 362.79 Mn |
| Jun 30, 2025 | 318.18 Mn |
| Mar 31, 2025 | 286.69 Mn |